Health and Fitness Health and Fitness
Mon, September 19, 2011
[ 03:00 PM ] - Market Wire
New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid
[ 03:00 PM ] - Market Wire
Research Suggests FORTEO® Significantly Increases Bone Strength
[ 03:00 PM ] - Market Wire
Alere Acquires Additional Shares of Axis-Shield
[ 02:15 PM ] - Market Wire
NeuroMetrix Reports Product Milestone
[ 01:30 PM ] - Market Wire
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Tuesday, September 20
[ 01:05 PM ] - Market Wire
Gileada?s Second Pivotal Phase 3 Clinical Study o .. roviral Quad Regimen Meets 48-Week Primary Object
[ 10:51 AM ] - Market Wire
Robbins Umeda LLP Announces an Investigation of Bovie Medical Corporation
[ 07:22 AM ] - Market Wire
Polaczenie kuracji lekiem ONGLYZAa" oraz insulino .. ch na cukrzyce typu 2 pozwala na zmniejszenie poz
[ 06:00 AM ] - Market Wire
PPD Appoints Raymond Hill as Chief Executive Officer and Member of the Board of Directors
[ 05:30 AM ] - Market Wire
FDA Panel to Review AtriCurea?s Synergy Ablation System on October 26
[ 05:30 AM ] - Market Wire
Wright Medical Group, Inc. Names Robert J. Palmisano President and Chief Executive Officer
[ 05:00 AM ] - Market Wire
Mercka?s ISENTRESS® (raltegravir) in Combination .. y and Tolerability in an Observational Trial in a
[ 04:05 AM ] - Market Wire
Inhibitex Commences Dosing of Phase 2 Clinical Tr .. of INX-189 in HCV Infected Genotype 2/3 Patients
[ 02:48 AM ] - Market Wire
Extensin de un estudio en fase de investigacin de .. liptina) incorporado a la insulina en adultos con
[ 02:48 AM ] - Market Wire
ONGLYZAa" (saxagliptin) (saxagliptina) adicionado .. abetes tipo 2 manteve redues nos nveis de acar no
[ 12:00 AM ] - Market Wire
Cord Blood America Updates Investors on Laboratory Licensing
Sun, September 18, 2011
[ 06:39 AM ] - Market Wire
Sangamo BioSciences Announces Presentation of Gro .. a From ZFN Therapeutic for HIV/AIDS at ICAAC 2011
Sat, September 17, 2011
[ 09:21 PM ] - Market Wire
Prolia® (Denosumab) Phase 2 Extension Study Show .. one Mineral Density Over Eight Years of Treatment
[ 05:22 AM ] - Market Wire
Dans le cadre de la prolongation d';&# .. ntale,;;;;; ONGLYZAa" (saxagli
[ 05:22 AM ] - Market Wire
Dans le cadre de la prolongation d';&# .. e,;;;; ONGLYZAa" (saxagliptine) p
[ 05:22 AM ] - Market Wire
Dans le cadre de la prolongation d';&# .. 4;;; ONGLYZAa" (saxagliptine) plus insu
[ 05:22 AM ] - Market Wire
Dans le cadre de la prolongation d'une ©tude exp .. tine) plus insuline chez les patients adultes att
[ 05:22 AM ] - Market Wire
Dans le cadre de la prolongation d'une ©tude exp .. ptine) plus insuline chez les patients adultes at
[ 05:12 AM ] - Market Wire
ONGLYZAa" (saxagliptin) se aggiunto a insulina in .. tipo 2 mantiene le riduzioni dei livelli di glic
[ 05:12 AM ] - Market Wire
ONGLYZAa" (saxagliptin) se aggiunto a insulina in .. tipo 2 mantiene le riduzioni dei livelli di glic
[ 05:12 AM ] - Market Wire
ONGLYZAa" (saxagliptin) se aggiunto a insulina in .. tipo 2 mantiene le riduzioni dei livelli di glic
[ 05:12 AM ] - Market Wire
ONGLYZAa" (saxagliptin) se aggiunto a insulina in .. tipo 2 mantiene le riduzioni dei livelli di glic
Fri, September 16, 2011
[ 04:40 PM ] - Market Wire
Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
[ 04:40 PM ] - Market Wire
Misonix Schedules Fourth Quarter and Year-End Fis .. nference Call;; September 20, 2011 at 4:30
[ 01:17 PM ] - Market Wire
Fibrocell Science, Inc. Announces New Presentation Time at the UBS Global Life Sciences Conference

Fibrocell Science, Inc. Announces New Presentation Time at the UBS Global Life Sciences Conference


Published on 2011-09-16 13:27:25 - Market Wire
  Print publication without navigation


EXTON, Pa.--([ BUSINESS WIRE ])--Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that its presentation at the UBS Global Life Sciences Conference to be held on September 19-21, 2011 at the Grand Hyatt Hotel in New York has been rescheduled to a different time.

David Pernock, the Companya™s Chairman and CEO, is now scheduled to present on Tuesday, September 20, at 12:00 p.m. Eastern Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company's website at [ www.fibrocellscience.com ].

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit [ www.fibrocellscience.com ].

Contributing Sources